This panel features insights from industry leaders on their organization’s pipeline, the advanced therapy investment landscape, and the regulatory, manufacturing, and commercial needs to successfully bring an advanced therapy to market.

Learn how specializing in planning and implementing complex biomanufacturing strategies has led to the construction of more than a dozen manufacturing facilities.

This panel discussion features insights from industry leaders on the key considerations to make when preparing for the launch of an advanced therapy, including pricing decisions and the evidence used to support payer and HTA engagement.

Listen to a panel of gene therapy experts with unique perspectives and real-world experiences share successful approaches in gene therapy development, CDx development and commercialization.

In this webinar co-sponsored by Precision ADVANCE and Project Farma, a panel of industry experts discuss the challenges faced when building a cutting-edge cell therapy manufacturing facility.

Considerations for the Clinical Development of Cell & Gene Therapies is a 2-part panel discussion with our Precision experts and C-Suite leaders from advanced therapy companies on the front lines of development. Part 1 discusses Cell Therapy development, and Part 2 discusses Gene Therapy development.

In this Precision ADVANCE panel, industry experts share perspectives on the current state of the cell and gene therapy industry and provide key insights in shortening time-to-market for advanced therapies.

In this webinar, Carolyn Morgan of PRECISIONeffect moderates an expert panel exploring the challenges of commercializing a cell or gene therapy from industry trailblazers that share lessons learned from prior launches and discuss how cell and gene therapies are reshaping commercializing strategies. Some of the topics explored will be tensions between cost-effectiveness and affordability, evidence generation strategies and development, and communication to payers and health technology appraisal organizations.

In this video, Precision experts Megan Liles and Deborah Phippard, PhD highlight the advantages that Precision ADVANCE brings to the lab.

Need help unravelling the complexity of CGTx development? Four experts explain Precision ADVANCE’s unique approach. Spend 50 seconds with Anshul Mangal, Deb Phippard, Megan Liles, and Philip Cyr.

Watch the available video to plan for success in the development of Diagnostic Assays for gene therapies.

Watch the available video to learn more about the team that led the industrialization of the most notable FDA-approved advanced therapies—and then created the world’s largest cell and gene therapy manufacturing footprint. 

Rare disease trials are complex under the best of circumstances—and the coronavirus pandemic has only complicated things. In this podcast, Precision’s Thijs Opdeweegh, Director, Clinical Business Solutions, and Kristi Clark, Senior Vice President, Project Management and Clinical Operations, explore the impact of decentralized operations on rare disease patients, and which new approaches are likely to become the “new normal” after COVID.